About 5 results found for searched term "PR-619" (0.136 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2565 | PR-619 | Deubiquitinase |
| 2,6-Diamino-3,5-dithiocyanopyridine | ||
| PR-619 is a broad-spectrum reversible DUB (deubiquitinating enzyme) inhibitor of USP2, USP4, USP5, USP7 and USP8 with an EC50 of 3-9 μM. PR-619 also induces endoplasmic reticulum stress and endoplasmic reticulum stress-associated apoptosis. | ||
| M5130 | Cisapride | 5-HT Receptor |
| R 51619; (±)-Cisaprid | ||
| Cisapride(R 51619) is a nonselective 5-HT4 receptor agonist, it is also a potent hERG potassium channel inhibitor. IC50 Value is 0.14 μM (EC50 for 5-HT4 receptor). | ||
| M6876 | L-161982 | Prostaglandin Receptor |
| L161982 | ||
| L-161982 is a EP4 receptor antagonist that is selective over all other members of the prostanoid receptor family (Ki values are 0.024, 0.71, 1.90, 5.10, 5.63, 6.74, 19 and 23 μM for human EP4, TP, EP3, DP, FP, IP, EP1 and EP2 receptors respectively). L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. | ||
| M10943 | Atabecestat | BACE |
| JNJ-54861911 | ||
| Atabecestat (JNJ-54861911) is a potent brain-osmotic and has oral activity β-position amyloid precursor protein lyase 1 (BACE1 inhibitors that strongly reduce the expression of Aβ protein in cerebrospinal fluid. Atabecestat (JNJ-54861911) is tolerant and has sustained pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Atabecestat (JNJ-54861911) has the potential to be used in the study of Alzheimer's disease. | ||
| M29143 | NTP42 | Prostaglandin Receptor |
| NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca2+] mobilization following stimulation of cells with the alternative TP agonist U46619. NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
